Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Generation of heterozygous SAMD9 CRISPR/Cas9-edited iPSC line (ESi086-A-3), carrying I1567M mutation

dc.contributor.authorPera, Joan
dc.contributor.authorCastaño, Julio
dc.contributor.authorCasamitjana, Joan
dc.contributor.authorGiorgetti, Alessandra
dc.contributor.authorRomero Moya, Damià
dc.date.accessioned2022-11-24T18:15:07Z
dc.date.available2022-11-24T18:15:07Z
dc.date.issued2022-09-03
dc.date.updated2022-11-24T18:15:07Z
dc.description.abstractGermline SAMD9 mutations are one of the most common alterations that predispose to pediatric myelodysplastic syndrome (MDS), a clonal disorder characterized by ineffective hematopoiesis, increasing the risk of developing acute myeloid leukemia (AML). Up to date, a disease model to study the role of SAMD9 mutation in MDS is still lacking. Here, we have generated a human induced pluripotent stem cell (hiPSC) line carrying SAMD9mut (p.I1567M), taking advantage of CRISPR/Cas9 system. As a result, the genetic engineered hiPSC line represent a new in vitro disease model to understand the impact of SAMD9 mutation at molecular and cellular level during hematopoiesis.
dc.format.extent6 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec726964
dc.identifier.issn1873-5061
dc.identifier.pmid36087523
dc.identifier.urihttps://hdl.handle.net/2445/191092
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.scr.2022.102906
dc.relation.ispartofStem Cell Research, 2022, vol. 64, p. 102906
dc.relation.urihttps://doi.org/10.1016/j.scr.2022.102906
dc.rightscc-by (c) Pera, Joan et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationCèl·lules mare
dc.subject.classificationLeucèmia mieloide
dc.subject.classificationMutació (Biologia)
dc.subject.otherStem cells
dc.subject.otherMyeloid leukemia
dc.subject.otherMutation (Biology)
dc.titleGeneration of heterozygous SAMD9 CRISPR/Cas9-edited iPSC line (ESi086-A-3), carrying I1567M mutation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
726964.pdf
Mida:
2.7 MB
Format:
Adobe Portable Document Format